HC Wainwright Maintains Buy on ProQR Therapeutics With $8 Price Target

HC Wainwright & Co. has maintained its Buy rating on ProQR Therapeutics's stock, setting a price target of $8.00. This target suggests a potential upside of 381.9% from the stock's closing price of $1.66 on September 30.